Article info

Download PDFPDF
Original article
Phenotypical difference in deamination of cytarabine is not evident in induction therapy for acute myeloid leukaemia

Authors

  1. Correspondence to Professor Per Hartvig Honoré, Faculty of Health and Medical Sciences, Department of Drug design and Pharmacology, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark; peh{at}sund.ku.dk
View Full Text

Citation

Krogh-Madsen M, Honoré SH, Jensen MK, et al
Phenotypical difference in deamination of cytarabine is not evident in induction therapy for acute myeloid leukaemia

Publication history

  • Received December 12, 2012
  • Accepted February 11, 2013
  • First published March 1, 2013.
Online issue publication 
May 17, 2013

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.